Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer.

Abstract

OPINION STATEMENT:

Approximately 15-20% of breast cancers (BC) demonstrate HER2 overexpression/gene amplification. Historically, before the era of HER2-directed therapies, this subtype was associated with poor prognosis. Anti-HER2 agents dramatically changed the natural course of disease and significantly prolonged patients' survival. In recent years, a number of new anti-HER2 therapies have been developed, and their approvals offer new therapeutic options for patients with advanced HER2-positive breast cancer. At present, HER2 pathway blocking drugs used in the treatment of metastatic breast cancer worldwide include trastuzumab and pertuzumab in the first-line treatment; trastuzumab deruxtecan and trastuzumab emtansine in the second line; and tucatinib, neratinib, lapatinib, and margetuximab in further lines of treatment of advanced HER2 positive breast cancer. Additionally, there are many clinical trials underway evaluating drugs blocking the HER2 pathway in advanced disease setting. This article presents new treatment options, discussing the most important findings from clinical trials and real-world reports, clinical benefits and risks of treatment, as well as efficacy of re-treatment with trastuzumab in metastatic breast cancer. New data challenge the current standards, and a number of questions arise regarding the optimal sequence of anti-HER2 targeted therapies, the optimal combination, including endocrine agents in luminal HER2 positive tumors and treatment of special patient population such as patients with brain metastases (BM).

• Authors: Malwina Stanowicka-Grada, Elżbieta Senkus
• Journal: Current treatment options in oncology (Curr Treat Options Oncol) Vol. 24 Issue 11 Pg. 1633-1650 (Nov 2023) ISSN: 1534-6277 [Electronic] United States
• PMID: 37878202 (Publication Type: Journal Article, Review)
• Copyright: © 2023. The Author(s).

Chemical References

• Receptor, ErbB-2
• Trastuzumab
• Ado-Trastuzumab Emtansine
• Lapatinib

Topics

• Humans
• Female
• Breast Neoplasms (drug therapy, genetics, metabolism)
• Receptor, ErbB-2 (metabolism)
• Trastuzumab (therapeutic use)
• Ado-Trastuzumab Emtansine (therapeutic use)
• Lapatinib (therapeutic use)